Report

Metformin Combined LMWH Intervention in 25 Pregnant Women with History of Hyperlipidemia Pancreatitis in Pregnancy Open Access

Mei Peng, Ya-Li Deng, Ling Yu, Yan-Ting Nie, Ting Luo, Jian Huang, Xi-Hong Zhou, Yi Ling Ding

June 16, 2021

DOI:10.36316/gcatr.03.0043

ABSTRACT

Objective: To explore the early preventive treatment of hypertriglyceridemia-induced acute pancreatitis (HTGP) in pregnancy.

Methods: A retrospective cohort analysis was performed to examine the drug intervention on recurrent HTGP and related pregnancy outcomes among women who had HTGP in their past pregnancy and developed hyperlipidemia during the second pregnancy. Participants were identified through inpatient case records under a single physician at the clinic and divided into two groups. The intervention group was given metformin lipid-lowering combined with low-molecular-weight heparin to prevent thrombosis when hypertriglyceridemia was developed during the pregnancy. In contrast, the non-intervention group includes those who did not receive active drug treatment until they developed recurrent HTGP. Metabolic markers were also examined by comparing them with their respective past pregnancies.

Results: All participants experienced elevated triglycerides during their two consecutive pregnancies. No pregnant women developed HTGP in the intervention group (n=12), while 10 of 13 (76.9%) women developed HTGP in the non-intervention group. Thus, the outcome seemed to be markedly different. In the intervention group, 11 women were gestated to term, and one was premature; one of 12 (8.3%) births was neonatal asphyxia; there was no low-weight birth, and the prognosis of mother and baby was favorable. Of 10 women who developed recurrent HTGP in the non-intervention group, four suffered from fetal loss, four had premature, and two had full-term delivery; among the three pregnant women without HTGP, one had a premature and two had full-term births; five of thirteen (38.5%) births were neonatal asphyxia.

Conclusion: Pregnant women with HTGP history, if not treated, are likely to develop the condition recurrently during pregnancy, but timely intervention on hypertriglyceridemia with lipid-lowering and thrombosis-preventing seemed complete to reduce the recurrent HTGP and improve the pregnancy outcomes.

KEYWORDS

Metformin; low molecular weight heparin; triglyceride; pregnancy; hyperlipidemia; HTGP.

Copyright©2021 by the author.

Licensee Global Clinical and Translational Research. This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution License (CCBY4.0, https://creative-commons.org/ licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited

How to cite this article:

Peng M, Deng YL, Yu L, Nie YT, Luo T, Huang J, Zhou XH, Ding YL. Metformin Combined LMWH Intervention in 25 Pregnant Women with History of Hyperlipidemia Pancreatitis in Pregnancy. Glob Clin Transl Res. 2021; 3(2):37-46. DOI:10.36316/gcatr.03.0043

REFREENCES

1. Herfort K, Fialova V, Srp B. Acute pancreatitis in pregnancy. Mater Med Pol. 1981;13(1):15-7.

2. Crisan LS, Steidl ET, Rivera-Alsina ME. Acute hyperlipidemic pancreatitis in pregnancy. Am J Obstet Gynecol. 2008; 198 (5):e57-9.

3. Papadakis EP, Sarigianni M, Mikhailidis DP, Mamopoulos A, Karagiannis V. Acute pancreatitis in pregnancy: an overview. Eur J Obstet Gynecol Reprod Biol. 2011;159(2):261-6.

4. Igbinosa O, Poddar S, Pitchumoni C. Pregnancy-associated pancreatitis revisited. Clin Res Hepatol Gastroenterol. 2013; 37(2):177-81.

5. Jain P. Acute pancreatitis in pregnancy: an unresolved issue. World J Gastroenterol. 2010;16(16):2065-6.

6. Guo YY, Li HX, Zhang Y, He WH. Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechan-isms and treatment modalities. Discov Med. 2019; 27(147): 101-9.

7. Li HL, Jiang YH, Wei Y, Zhao YY, Zhu X, Yao GQ. [Clinical analysis of acute hyperlipidemic pancreatitis during preg-nancy and postpartum period]. Beijing Da Xue Xue Bao Yi Xue Ban. 2014;46(1):125-9.

8. Lippi G, Albiero A, Montagnana M, Salvagno GL, Scevarolli S, Franchi M, et al. Lipid and lipoprotein profile in physiolo-gical pregnancy. Clin Lab. 2007;53(3-4):173-7.

9. Athyros VG, Giouleme OI, Nikolaidis NL, Vasiliadis TV, Bouloukos VI, Kontopoulos AG, et al. Long-term follow-up of patients with acute hypertriglyceridemia-induced pan-creatitis. J Clin Gastroenterol. 2002;34(4):472-5.

10. Kraemer H. A Comment on “Beyond P-value: the Rigor and Power of Study”. Glob Clin Transl Res. 2020;2(1):7-9.

11. Morita Y, Yoshikawa T, Takeda S, Matsuyama K, Takahashi S, Yoshida N, et al. Involvement of lipid peroxidation in free fatty acid-induced isolated rat pancreatic acinar cell injury. Pancreas. 1998;17(4):383-9.

12. Zafar U, Hassan J, Ismail K, Agha S, Memon Z, Bhatty S. Effectiveness of Probiotics, Metformin and Their Combi-nation Therapy in Ameliorating Dyslipidemia Associated With PCOS. Journal of Pharmaceutical Research Interna-tional. 2019;30(4):1-9.

13. Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr. 2000;71(5 Suppl):1256S-61S.

14. Fortson MR, Freedman SN, Webster PD, 3rd. Clinical assess-ment of hyperlipidemic pancreatitis. Am J Gastro-enterol. 1995;90(12):2134-9.

15. Kampmann U, Knorr S, Fuglsang J, Ovesen P. Determinants of Maternal Insulin Resistance during Pregnancy: An Updated Overview. Journal of Diabetes Research. 2019; 2019:5320156.

16. Mali P. Pancreatitis in pregnancy: etiology, diagnosis, treat-ment, and outcomes. Hepatobiliary Pancreat Dis Int. 2016; 15(4):434-8.

17. Chuang TY, Chao CL, Lin BJ, Lu SC. Gestational hyper-lipidemic pancreatitis caused by type III hyperlipopro-teinemia with apolipoprotein E2/E2 homozygote. Pancreas. 2009;38(6):716-7.

18. Bildirici I, Esinler I, Deren O, Durukan T, Kabay B, Onderoglu L. Hyperlipidemic pancreatitis during pregnancy. Acta Obstet Gynecol Scand. 2002;81(5):468-70.

19. Spracklen CN, Saftlas AF, Triche EW, Bjonnes A, Keating B, Saxena R, et al. Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia. Am J Hypertens. 2015;28(7):915-23.

20. Valdivielso P, Ramírez-Bueno A, Ewald N. Current know-ledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25(8):689-94.

21. Ismail OZ, Bhayana V. Lipase or amylase for the diagnosis of acute pancreatitis? Clin Biochem. 2017;50(18):1275-80.

22. Barbour LA, Shao J, Qiao L, Pulawa LK, Jensen DR, Bartke A, et al. Human placental growth hormone causes severe insulin resistance in transgenic mice. American Journal of Obstetrics and Gynecology. 2002;186(3):512-7.

23. Garg A. Insulin Resistance in the Pathogenesis of Dyslipid-emia. Diabetes Care. 1996;19(4):387.

24. Chodick G, Tenne Y, Barer Y, Shalev V, Elchalal U. Gestational diabetes and long-term risk for dyslipidemia: a population-based historical cohort study. BMJ Open Diabetes Research & Care. 2020;8(1):e000870.

25. Kim WM, Merskey C, Deming QB, Adel HN, Wolinsky H, Clarkson TB, et al. Hyperlipidemia, Hypercoagulability, and Accelerated Thrombosis: Studies in Congenitally Hyper-lipidemic Rats and in Rats and Monkeys With Induced Hyperlipidemia. Blood. 1976;47(2):275-86.

26. American Diabetes Association. Management of dyslipi-demia in adults with diabetes. Diabetes Care. 2000;23 Suppl 1:S57-60.

27. Kjos SL, Buchanan TA, Montoro M, Coulson A, Mestman JH. Serum Lipids Within 36 mo of Delivery in Women With Recent Gestational Diabetes. Diabetes. 1991;40 (Supp-lement 2):142.

28. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996; 334(9): 574-9.

29. Wu RR, Zhang FY, Gao KM, Ou JJ, Shao P, Jin H, et al. Metformin treatment of antipsychotic-induced dyslipid-emia: an analysis of two randomized, placebo-controlled trials. Mol Psychiatry. 2016;21(11):1537-44.

30. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993;16(10):1387-90.

31. Peng M, Huang J, Ding Y. Preventive Management of Hypertriglycer-idemia in Pregnancy. Glob Clin Transl Res. 2020;2(3):73-7.

32. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications as Mono-therapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164(11):740-51.

33. Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a syste-matic review. Metabolism. 2013;62(11):1522-34.

34. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-74.

35. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56(9):1898-906.

36. Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. metformin inhibits hepatic gluconeo-genesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355-69.

37. Perseghin G. Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. Diabetes care. 2009;32(suppl 2):S164-S7.

38. Medak KD, Townsend LK. Adding more fat to a high‐fat diet only exacerbates hepatic insulin resistance. The Journal of physiology. 2019;597(6):1435.

39. Su Z, Nie Y, Huang X, Zhu Y, Feng B, Tang L, et al. Mitophagy in Hepatic Insulin Resistance: Therapeutic Potential and Concerns. Frontiers in Pharmacology. 2019;10(1193).

40. Panarotto D, Rémillard P, Bouffard L, Maheux P. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. European Journal of Clinical Investigation. 2002; 32(2):84-92.

41. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl). 2002;80(12):753-69.

42. Huang Y, Li X, Wang M, Ning H, A L, Li Y, et al. Lipoprotein lipase links vitamin D, insulin resistance, and type 2 diabetes: a cross-sectional epidemiological study. Cardio-vasc Diabetol. 2013;12:17.

43. Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res. 1994;35(2):177-93.

44. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994;17(10): 1093-9.

45. Silveira A. Postprandial triglycerides and blood coagulation. Exp Clin Endocrinol Diabetes. 2001;109(4):S527-32.

46. Qiu Q, Li GJ, Tang L, Guo Y, Wen LZ, Wang B, et al. The efficacy of low molecular weight heparin in severe acute pancreatitis: A systematic review and meta-analysis of randomized controlled trials. J Dig Dis. 2019;20(10):512-22.

47. Du JD, Zheng X, Huang ZQ, Cai SW, Tan JW, Li ZL, et al. Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancrea-titis. Exp Ther Med. 2014;8(1):141-6.

48. Xu H-B, Jiang R-H, Sheng H-B. Meta-analysis of the effects of Bifidobacterium preparations for the prevention and treatment of pediatric antibiotic-associated diarrhea in China. Complementary Therapies in Medicine. 2017; 33: 105-13.

49. Wan Y-M, Zhu Y-Q, Xia B, Luo J. Treating TNBS-induced colitis in rats with probiotics. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2011;22(5):486-93.

50. Gulan T, Yeernuer T, Sui S, Mayinuer N. A Rat Model of Maternal Polycystic Ovary Syndrome Shows that Exposure to Androgens In Utero Results in Dysbiosis of the Intestinal Microbiota and Metabolic Disorders of the Newborn Rat. Medical science monitor : international medical journal of experimental and clinical research [Internet]. 2019 2019/12//; 25:[9377-91 pp.]. Available from:https://doi.org/10.12659/MSM.918600.

51. Wang C, Zhang C, Li S, Yu L, Tian F, Zhao J, et al. Effects of Probiotic Supplementation on Dyslipidemia in Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Cont-rolled Trials. Foods. 2020;9(11).

52. Fortes PM, Marques SM, Viana KA, Costa LR, Naghettini AV, Costa PS. The use of probiotics for improving lipid profiles in dyslipidemic individuals: an overview protocol. Syst Rev. 2018;7(1):165.

53. Guo Z, Liu XM, Zhang QX, Shen Z, Tian FW, Zhang H, et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis. 2011;21(11):844-50.

54. Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20 (42): 15518-31.

55. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr. 2009;139(5):905-11.

56. Foley MH, O’Flaherty S, Allen G, Rivera AJ, Stewart AK, Barrangou R, et al. Lactobacillus bile salt hydrolase substrate specificity governs bacterial fitness and host colonization. Proceedings of the National Academy of Sciences. 2021;118(6):e2017709118.

57. Adebola OO, Corcoran O, Morgan WA. Prebiotics may alter bile salt hydrolase activity: Possible implications for cholesterol metabolism. PharmaNutrition. 2020; 12: 100182.